Minneapolis, MNNCT07560865Now EnrollingIRB Ready

Astrocytoma Clinical Trial in Minneapolis, MN

Access cutting-edge astrocytoma treatment through this phase 1 clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Sponsored by Masonic Cancer Center, University of Minnesota

Quick Self-Assessment

See if you qualify for this Minneapolis location

Preparing your pre-screening questions…

Expert Care in Minneapolis

Access astrocytoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related astrocytoma treatment provided free

Apply for This Minneapolis Location

Check if you qualify for this astrocytoma clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneapolis

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneapolis site if eligible
  4. 4Begin participation

About This Astrocytoma Study in Minneapolis

This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally

Sponsor: Masonic Cancer Center, University of Minnesota

Who Can Participate

Inclusion Criteria

Histologically confirmed WHO Grade 4 astrocytoma from archival tissue. IDH mutation status and MGMT promoter methylation status will not limit candidacy but needs to be known.
Evidence of first or second cancer recurrence/ progression by magnetic resonance imaging (MRI) for which a gross tumor resection (GTR) is feasible as determined by the primary investigator in concordance with the study-affiliated neurosurgeon.
Previous completed SOC antitumor treatment including surgery, radiation therapy, and temozolomide +/- Optune/ Tumor Treatment Fields (TTF).
No concurrent alternative curative therapy, including use of TTF.
Able to undergo standard MRI scans with contrast agent throughout the course of the study.
≥ 18 years and ≤ 75 years of age at the time of consent.
Karnofsky performance status ≥70.
Must be completely off or on a dose of dexamethasone 2mg daily or less with stable neurological function at the time of enrollment.
Adequate organ function within 14 days of study treatment start as defined in Section 4.1.9 of the protocol.
Participants of childbearing potential (POCBP) or with partners of childbearing potential must use a highly effective form of contraception from the time of the screening visit until at least 3 months after the dose of FT536.
Must agree to and sign the consent for the companion Long-Term Follow-Up study (CPRC# 2021LS077).
Voluntary written consent prior to the performance of any research related procedures.
Agree to stay in the Twin Cities metropolitan area (i.e. within a 45-minute drive of the UMN) from the time of biopsy through hospital discharge following completion of the planned craniotomy.

Exclusion Criteria

Clinically significant increased intracranial pressure (e.g., impending herniation or requirement for immediate palliative treatment) or uncontrolled seizures or any other situation requiring urgent neurosurgical intervention.
History of myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML) or with features suggestive of MDS/ AML.
Radiographic evidence of leptomeningeal disease.
Received prior treatment with bevacizumab or any other cellular therapy available on or off a clinical trial.
Non-malignant CNS disease such as CNS vasculitis or neurodegenerative disease.
Prior or current GammaTile, Gliadel wafer use, or other implanted therapeutic agent or photodynamic therapy.
Any known condition that requires systemic immunosuppressive therapy - inhaled and topical steroids are permitted.
Pregnant or breastfeeding. Menstruating POCBP must have a negative pregnancy test within 14 days before the planned biopsy. Patient must agree to use highly effective method of birth control from the time of the screening visit until at least 3 months after the dose of FT536.
Known seropositive for HIV or known Hepatitis B or C infection with detectable viral load by PCR.
Prior history of malignancy within 5 years of enrollment other than basal or squamous cell carcinoma of the skin, cervical intra-epithelial neoplasia, in situ carcinoma of the breast, or prostate cancer treated with surgery or RT with a prostate specific antigen of \<0.01 ng/mL tested within 28 days of trial enrollment.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pec

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT07560865) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Astrocytoma Treatment Options in Minneapolis, MN

If you're searching for astrocytoma treatment options in Minneapolis, MN, this clinical trial (NCT07560865) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced astrocytoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all astrocytoma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Minneapolis, MN

See all brain cancer clinical trials recruiting in Minneapolis — not just this study.

Browse Brain Cancer Trials in Minneapolis →

Browse More Trials by Condition

Brain Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Minneapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneapolis, MN